Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Insight Genetics and Vanderbilt-Ingram Cancer Center Partner

Published: Wednesday, March 05, 2014
Last Updated: Tuesday, March 04, 2014
Bookmark and Share
Research collaboration includes exclusive licensing agreement to commercialize a new genetic test that will improve treatment selection for breast cancer patients with poor prognosis.

Insight Genetics, Inc. is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to enhance how researchers and oncologists classify and treat patients diagnosed with triple-negative breast cancer (TNBC).

The molecular diagnostics company is working with VICC scientists to identify genetic markers that will help select the targeted therapeutics most effective for each individual TNBC patient.

The American Cancer Society estimates that more than 230,000 women will be diagnosed with an invasive form of breast cancer in 2014. Many of these cases can be genetically characterized as Estrogen Receptor (ER)-positive, Progesterone Receptor (PR)-positive or HER2-positive.

These characterizations are important because they assist clinicians in matching patients with targeted therapeutic options. Breast tumors that do not express genes for any of these three known markers are classified as triple-negative breast cancers. Patients with TNBC currently have limited treatment options and a higher risk of relapse than other forms of the disease.

As part of their research project, Insight Genetics will be collaborating with Jennifer Pietenpol, Ph.D., director of VICC, and B.F. Byrd Jr., Professor of Oncology, as well as the laboratory group at VICC in a continuation of their work to identify novel genetic markers for TNBC.

Recent work from the Pietenpol laboratory published in the Journal of Clinical Investigation used an algorithm to examine gene expression data from more than 500 TNBC cases and identified up to six distinct sub-types of triple-negative breast cancers.

Insight Genetics and Dr. Pietenpol will now focus on identifying novel genetic drivers for these various TNBC sub-types and developing a better understanding of effective treatment options for each. The work is also designed to identify new TNBC biomarkers and develop assays based on these biomarkers.

“We are enthusiastic to be entering into this research collaboration and licensing agreement with Vanderbilt,” said Eric Dahlhauser, Chairman and CEO of Insight Genetics. “Dr. Pietenpol’s work shows tremendous promise for identifying unique treatment options for each molecular sub-type of triple-negative breast cancer. We look forward to working closely with her and her colleagues at Vanderbilt-Ingram Cancer Center as we apply our expertise in assay design and commercialization to improve treatment development and selection for this population of cancer patients.”

As part of its licensing agreement with VICC, Insight Genetics obtained exclusive worldwide rights to the patent application PCT/US12/65724 entitled “Markers of the Triple-Negative Breast Cancer and Uses Thereof” that will be used to develop and commercialize molecular assays to determine the TNBC subtypes.

Insight Genetics also received commercial rights to the TNBCtype© software algorithm (Chen et.al. Cancer Informatics 2012:11 147-156), a web-based service that interprets raw data obtained through independent genetic sequencing methods.

Insight Genetics’ agreement with VICC expands the company’s existing portfolio of advanced diagnostic tools to improve the lives of cancer patients, including multiple diagnostic assays for lung and other cancers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Insight Genetics Announces Promotions for Two Team Members
Kasey Lawrence has been named Senior Technology Specialist, and Tyler Nielsen has been appointed Research Scientist.
Thursday, August 21, 2014
Insight Genetics Awarded NCI Contract
Company receives Phase II Award to continue development of a companion diagnostic test for drugs targeting anaplastic lymphoma kinase.
Tuesday, January 07, 2014
Insight Genetics Launches Insight Molecular Labs
CLIA-certified laboratory offers diagnostic tests that identify specific cancer biomarkers.
Friday, December 13, 2013
Insight Genetics and National Cancer Institute Collaborate to Develop New Technologies for Clinical Trials
Insight Genetics has developed a diagnostic test that can more accurately determine if certain lung cancer patients will respond to targeted therapies.
Tuesday, April 02, 2013
Insight Genetics Promotes Four
Molecular diagnostics company builds expertise and depth in research, application and commercial development of companion diagnostics to improve cancer care.
Wednesday, February 13, 2013
Insight Genetics Awarded Qualifying Therapeutic Discovery Program Grant
Diagnostics Company Receives Funds to Advance Cancer Care.
Wednesday, November 17, 2010
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!